Navigation Links
Valeant Pharmaceuticals to Syndicate Incremental Term Loans
Date:11/30/2011

MISSISSAUGA, Ontario, Nov. 30, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced plans to syndicate $350 million of incremental term loans under its existing senior secured credit facilities to partially fund its previously announced acquisition of iNova.  The incremental term loans will mature in April 2016 and are expected to have terms that are consistent with the Company's existing $1.725 billion Term Loan A facility. The incremental term loans are expected to close in December 2011, subject to market and other customary conditions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
2. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
3. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
4. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
5. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
6. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
7. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
8. Valeant Pharmaceuticals to Present at Industry Conferences
9. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
10. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
11. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class ... . , The healthcare industry in the United States has undergone major changes over ... of needing to have a doctor’s order to get a blood test or other ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
(Date:8/16/2017)... ... 16, 2017 , ... “God Will Break Every Chain”: an inspirational story for those shackled by ... of published author, Evangelist Joann Shivers, a writer and a woman of great faith and ... at an early age. She was born and raised in Vero Beach, Florida and ...
(Date:8/15/2017)... ... August 15, 2017 , ... Medicine ... out to a patient who feels isolated. It’s developing relationships and thereby growing ... President Daniel R. Wilson, MD, PhD, invited three renowned authors and academic leaders ...
Breaking Medicine News(10 mins):